Heterogeneous tumour growth and repigmentation of the B16‐G4F tumour led us to develop a non‐pigmented cell line (B16‐OVAmTYR−/−) by tyrosinase invalidation using CRISPR/Cas9. Here, TYR is linked to neoplasm.